SABS
SAB Biotherapeutics Inc
2.90$
+0.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | – | – | – | – | – | |
| – | – | 75.5% | 102.6% | 2.8% | 96.3% | 112.9% | 135.2% | 25.3% | – | 158.9% | 1,043.4% | 77.8% | 309.6% | 210.1% | 388.4% | – | 685.0% | – | – | – | – | – | – | – | |
| – | – | 24.5% | -2.6% | 97.2% | 3.7% | -12.9% | -35.2% | 74.7% | – | -58.9% | -943.4% | 22.3% | -209.5% | -110.1% | -288.4% | – | -585.0% | – | – | – | – | – | – | – | |
| – | – | 75.5% | 102.6% | 102.4% | 96.3% | 112.9% | 135.2% | 204.1% | – | 776.3% | 4,254.8% | 317.3% | 1,408.8% | 860.1% | 2,584.3% | – | 6,652.2% | – | – | – | – | – | – | – | |
| – | – | 19.7% | 13.2% | 24.5% | 70.1% | 43.9% | 67.9% | 112.7% | – | 593.2% | 3,391.1% | 202.9% | 4,878.8% | 443.5% | 1,384.4% | – | 2,328.7% | – | – | – | – | – | – | – | |
| – | – | 19.7% | 13.2% | 124.4% | 70.1% | 43.9% | 67.9% | 292.1% | – | 1,214.9% | 6,630.0% | 442.4% | 5,978.3% | 1,095.8% | 3,588.6% | – | 8,141.2% | – | – | – | – | – | – | – | |
| – | – | 4.8% | -15.8% | -27.2% | -66.4% | -56.8% | -103.0% | -217.5% | – | -1,273.8% | -7,573.4% | -420.1% | -6,188.0% | -1,205.9% | -3,877.0% | – | -8,726.3% | – | – | – | – | – | – | – | |
| – | – | 0.4% | 0.4% | 0.5% | 2.7% | 0.6% | 1.1% | 2.0% | – | 15.9% | 88.1% | 5.5% | 25.5% | 8.1% | 35.4% | – | 61.8% | – | – | – | – | – | – | – | |
| – | – | 8.3% | -16.2% | -27.7% | -104.5% | 9.1% | -76.7% | -197.1% | – | -1,265.5% | -8,046.1% | -402.7% | -7,493.8% | -532.1% | -2,787.7% | – | -9,934.5% | – | – | – | – | – | – | – | |
| – | – | 0.4% | 0.4% | 0.0% | 2.7% | 0.8% | -1.5% | -20.4% | – | 4.4% | 88.1% | 13.2% | 0.0% | -1,416.0% | – | – | 11,661.4% | – | – | – | – | – | – | – | |
| – | – | 8.3% | -16.2% | -27.7% | -104.5% | 8.4% | -75.2% | -197.1% | – | -1,265.5% | -8,046.1% | -402.7% | -7,493.8% | -532.1% | -2,787.7% | – | -9,934.5% | – | – | – | – | – | – | – | |
| – | – | 10.4% | -14.3% | -24.3% | -96.2% | 15.5% | -63.7% | -169.8% | – | -1,090.7% | -6,914.7% | -319.4% | -7,158.4% | -313.9% | -2,363.9% | – | -9,187.7% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.